BY COVID PROJECT

BeYond-COVID (BY-COVID) aims to provide comprehensive open data on SARS-CoV-2 and other infectious diseases across scientific, medical, public health and policy domains. It will strongly emphasise mobilising raw viral sequences, helping to identify and monitor the spread of SARS-CoV-2 variants. The project will further accelerate access to SARS-CoV-2 and COVID-19 and linking patient and research data.

To ensure interoperability of national and global efforts, BY-COVID will enable federated data analysis compliant with data protection regulations, harmonise and manage metadata and sample identifiers, and facilitate long-term cataloguing.

It will also develop synergies with the European Health Data Space.

Ultimately, it will improve European readiness for future pandemics, enhance genomic surveillance and rapid-response capabilities.

Project Coordinator

Led by ELIXIR

Participation in BY COVID

IACS participate in BY COVID. WP 5 leaders: Nina Van Goethem (Sciensano), Enrique Bernal Delgado (IACS)

Funding

BY-COVID receives funding from the European Union’s Horizon Europe Research and Innovation Programme under grant agreement number 101046203.

More information:

www.by-covid.org



PARTICIPATION BY COVID

The Work Packages will mobilise SARS-CoV-2 and other infectious disease data (i.e. make it easier to transfer to a data repository), connect and standardise the data (to make data searchable via the COVID-19 Data Portal and provide data management protocols), and expose and analyse the data (provide standardised analysis methods).

IACS lead work package 5 in this project.

WP5: A continuously evolving demonstrator project feeding the changing research questions that surface during an on-going pandemic to solutions.

Work Package 5 will demonstrate usability of BY-COVID services across disciplines and national borders through continuously evolving demonstrator projects. It will assess viral variants and disease outcomes using real world data, as well as the effectiveness of vaccines against new variants using retrospective clinical trial data and improve the understanding of the mechanistic determinants of variant responses.



BY COVID OUTCOMES

  • 20/12/2023
    Marjan Meurisse, Francisco Estupiñán-Romero, Javier González-Galindo, Natalia Martínez-Lizaga, Santiago Royo-Sierra, Simon Saldner, Lorenz Dolanski-Aghamanoukjan, Alexander Degelsegger-Marquez, Stian Soiland-Reyes, Nina Van Goethem & Enrique Bernal-Delgado for the BeYond-COVID project. Federated causal inference based on real-world observational data sources: application to a SARS-CoV-2 vaccine effectiveness assessment. BMC Med Res Methodol 23, 248 (2023). https://doi.org/10.1186/s12874-023-02068-3
  • 12/05/2023
    Estupiñán-Romero, Francisco, González-Galindo, Javier, Meurisse, Marjan, Martínez-Lizaga, Natalia, Royo-Sierra, Santiago, Van Goethem, Nina, & Bernal-Delgado, Enrique. (2023). BY-COVID – WP5 – Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment preliminary outputs from Aragon, Spain (0.0.2). Zenodo. https://doi.org/10.5281/zenodo.7930373
  • 20/04/2023
    Francisco Estupiñán-Romero, Nina Van Goethem, Marjan Meurisse, Javier González-Galindo, Enrique Bernal-Delgado. BY-COVID WP5 T5.2 baseline-use-case. https://github.com/by-covid/BY-COVID_WP5_T5.2_baseline-use-case

    This publication corresponds to the Research Objects (RO) of the Baseline Use Case proposed in T.5.2 (WP5) in the BY-COVID project on “COVID-19 Vaccine(s) effectiveness in preventing SARS-CoV-2 infection”.

  • 13/04/2023
    Meurisse, Marjan, Van Goethem, Nina, Estupiñán-Romero, Francisco, González-Galindo, Javier, Royo-Sierra, Santiago, Martínez-Lizaga, Natalia, & Bernal-Delgado, Enrique. (2023). BY-COVID – WP5 – Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment – Study protocol (1.0.3). Zenodo. doi.org/10.5281/zenodo.7825979
  • 06/02/2023
    Estupiñán-Romero, Francisco, Launa-Garcés, Ramón, Van Dam, Iris, Cosgrove, Shona, Van Goethem, Nina, & Bernal-Delgado, Enrique. (2023). BY-COVID Milestone 2.2 Mechanism for data access and use of routine real-world data. Zenodo. https://doi.org/10.5281/zenodo.7944195
  • 09/02/2023
    Natalia Martínez-Lizaga, Marjan Meurisse, Francisco Estupiñan-Romero, Nina Van Goethem, & Enrique Bernal-Delgado. (2023). BY-COVID – WP5 – Baseline Use Case: COVID-19 vaccine effectiveness assessment – Data Management Plan (0.0.1). Zenodo. doi.org/10.5281/zenodo.7625784
  • 26/01/2023
    Estupiñán-Romero, Francisco, Van Goethem, Nina, Meurisse, Marjan, González-Galindo, Javier, & Bernal-Delgado, Enrique. (2023). BY-COVID – WP5 – Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment – Common Data Model Specification (1.1.0). Zenodo. https://doi.org/10.5281/zenodo.7572373
  • 01/08/2022
    Giles, Tom, Quinlan, Phil, Belien, Jeroen, Lischke, Julia, Portell-Silva, Laura, Capella-Gutierrez, Salvador, Karki, Reagon, Kalaitzi, Vasso, Bernal-Delgado, Enrique, & Keppler, Antje. (2022). BY-COVID- D2.1 – Initial data and metadata harmonisation at domain level to enable fast responses to COVID-19 (V1.0). Zenodo. doi.org/10.5281/zenodo.7017728
  • 27/07/2022
    Estupiñán-Romero, Francisco, Van Goethem, Nina, Meurisse, Marjan, González-Galindo, Javier, & Bernal-Delgado, Enrique. (2022). BY-COVID – WP5 – Baseline Use Case: COVID-19 vaccine effectiveness assessment – Common Data Model Specification (1.0.0). Zenodo. https://doi.org/10.5281/zenodo.6913046
  • The ultimate outcome of the project is that SARS-CoV-2 and other infectious disease data will be easier to access, share and analyse.

    This will enable the world to respond more quickly to infectious disease outbreaks.



PARTNERS

The BY-COVID project has 53 partners across 19 countries and stakeholders from the biomedical field, hospitals, public health, social sciences and humanities. More information about partners.